

US00RE48404E

(19) **United States**
 (12) **Reissued Patent**
 Kim et al.

(10) **Patent Number:** US RE48,404 E
 (45) **Date of Reissued Patent:** *Jan. 26, 2021

(54) **HYBRID HEPATOCYTE GROWTH FACTOR GENE HAVING HIGH EXPRESSION EFFICIENCY OF TWO HETEROGENEITIES OF HEPATOCYTE GROWTH FACTOR**

(71) Applicant: **Helixmith Co., Ltd**, Seoul (KR)

(72) Inventors: **Jong-Mook Kim**, Seoul (KR); **Woong Hahn**, Goyang (KR); **Eun-Jin Park**, Seoul (KR)

(73) Assignee: **Helixmith Co., Ltd**, Seoul (KR)

(*) Notice: This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/642,307**

(22) Filed: **Jul. 5, 2017**

Related U.S. Patent Documents

Reissue of:

(64) Patent No.: **7,745,174**
 Issued: **Jun. 29, 2010**
 Appl. No.: **12/650,860**
 Filed: **Dec. 31, 2009**

U.S. Applications:

(60) Division of application No. 10/944,277, filed on Sep. 20, 2004, now Pat. No. 7,812,146, which is a continuation of application No. PCT/KR03/00548, filed on Mar. 20, 2003.

(30) **Foreign Application Priority Data**

Mar. 20, 2002 (KR) 10-2002-0015074

(51) **Int. Cl.**
C07K 14/475 (2006.01)

(52) **U.S. Cl.**
 CPC **C07K 14/4753** (2013.01)

(58) **Field of Classification Search**
 CPC A61P 1/16; C07K 14/4753
 See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

- 5,328,836 A 7/1994 Shima et al.
 5,500,354 A 3/1996 Kitamura et al.
 5,580,859 A 12/1996 Felgner et al.
 5,587,359 A 12/1996 Higashio et al.
 5,652,225 A 7/1997 Isner
 5,693,622 A 12/1997 Wolff et al.
 6,013,624 A 1/2000 Goldberg et al.
 6,121,246 A 9/2000 Isner
 6,248,722 B1 6/2001 Morishita et al.
 6,258,787 B1 7/2001 Isner
 6,316,419 B1 11/2001 Leiden et al.
 6,413,942 B1 7/2002 Felgner et al.
 6,498,144 B1 12/2002 Goldberg et al.
 6,706,694 B1 3/2004 Wolff et al.
 6,887,477 B1 5/2005 Nagano et al.
 7,285,540 B2 10/2007 Morishita et al.
 7,745,174 B2 6/2010 Kim et al.
 7,812,146 B2 10/2010 Kim et al.
 7,838,505 B2 * 11/2010 Kim A61P 1/16
 514/44 R

- 8,338,385 B2 * 12/2012 Kim A61P 1/16
 514/44 R
 8,389,492 B2 * 3/2013 Kim A61P 1/16
 514/44 R
 2002/0172663 A1 11/2002 Palasis
 2003/0148968 A1 8/2003 Hammond et al.
 2003/0171287 A1 9/2003 Morishita et al.
 2004/0105882 A1 6/2004 Morishita et al.
 2004/0228834 A1 11/2004 Isner et al.
 2005/0079581 A1 4/2005 Kim et al.
 2006/0286072 A1 12/2006 Giordano et al.
 2007/0059288 A1 3/2007 Dinsmore et al.
 2008/0268030 A1 10/2008 Morishita et al.
 2009/0004260 A1 1/2009 Morishita et al.
 2009/0082293 A1 3/2009 Giordano et al.
 2009/0131350 A1 5/2009 Kim et al.
 2009/0202606 A1 8/2009 Kim et al.
 2009/0258932 A1 10/2009 Kim et al.

FOREIGN PATENT DOCUMENTS

- | | | |
|----|----------------|---------|
| JP | 11-246433 | 9/1999 |
| KR | 2003-0075718 A | 9/2003 |
| WO | WO 98/50079 | 11/1998 |
| WO | WO 98/50079 A2 | 11/1998 |
| WO | WO 99/45775 | 9/1999 |
| WO | WO 99/45775 A1 | 9/1999 |
| WO | WO 01/34208 | 5/2001 |
| WO | WO 01/34208 A1 | 5/2001 |

(Continued)

OTHER PUBLICATIONS

- Folkman (Circulation. vol. 97, Issue 12, pp. 1108-1110). Mar. 31, 1998.*
 Courtney et al. (GenBank Accession No. AC004960 available since Jun. 12, 1998, Retrieved from Internet: <http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nucore&id=3845412>).
 European Search Report for European Application No. EP 03 74 4561, dated Apr. 18, 2006, European Patent Office, Munich, Germany.
 Office Action for U.S. Appl. No. 10/944,277, dated Jan. 9, 2008.
 Office Action for U.S. Appl. No. 10/944,277, dated Feb. 13, 2009.
 Notice of Allowance and Fees Due for U.S. Appl. No. 10/944,277, dated May 29, 2009.
 Notice of Allowance and Fees Due for U.S. Appl. No. 10/944,277, dated Oct. 23, 2009.
 Office Action for U.S. Appl. No. 11/957,170, dated Jan. 28, 2010. Esp@cenet Database, English language abstract of JP 11-246433 A, published Sep. 14, 1999 (listed as document B1 on the accompanying form PTO/SB/08A).
 Romano et al. Stem Cells, 1999, 17 :191-202.

(Continued)

Primary Examiner — Padmashri Ponnaluri

(74) *Attorney, Agent, or Firm* — Fenwick & West LLP

(57) **ABSTRACT**

The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.

18 Claims, 12 Drawing Sheets

Specification includes a Sequence Listing.

(56)

References Cited**FOREIGN PATENT DOCUMENTS**

- WO WO 02/089856 11/2002
 WO WO 02/089856 A1 11/2002

OTHER PUBLICATIONS

- Liu et al, Journal of Controlled Release vol. 78, Issues 1-3, Jan. 17, 2002, pp. 259-266.
- Schmitz et al, Gut. Jan. 2002; 50(1): 130-135.
- U.S. Appl. No. 12/650,860, inventors Kim et al., filed Dec. 31, 2009. Notice of Allowance and Fees Due for U.S. Appl. No. 12/650,860, dated Mar. 10, 2010.
- Gardilik, et al., "Vectors and delivery systems in gene therapy," Med Sci Monit 11(4):RA110-121 (2005).
- Kato et al., "Nonviral HVJ (hemagglutinating virus of Japan) liposome-mediated retrograde gene transfer of human hepatocyte growth factor into rat nervous system promotes functional and histological recovery of the crushed nerve," Neuroscience Research, 52, pp. 299-310, Elsevier Ireland Ltd and the Japan Neuroscience Society (2005).
- Patil, et al., "DNA-based Therapeutics and DNA Delivery Systems: A Comprehensive Review," The AAPS Journal 9(1) Article 9:E61-E77 (2005).
- Thomas, et al., "Progress and Problems with the use of viral vectors for gene therapy," Nature Reviews Genetics 4:346-358, Nature Publishing Group (2003).
- Yang, et al., "Sustained Expression of Naked Plasmid DNA Encoding Hepatocyte Growth Factor in Mice Promotes Liver and Overall Body Growth," Hepatology 33:848-859, American Assoc. for the Study of Liver Disease (2001).
- Notice of Allowance for U.S. Appl. No. 11/957,170 (now U.S. Pat. No. 7,838,505), dated Jul. 19, 2010.
- Office Action for U.S. Appl. No. 12/359,137, dated Apr. 28, 2011.
- Office Action for U.S. Appl. No. 12/421,425, dated Aug. 19, 2010.
- Office Action for U.S. Appl. No. 12/421,425, dated Dec. 17, 2010.
- U.S. Appl. No. 13/045,460, filed Mar. 10, 2011.
- File History of U.S. Appl. No. 12/650,860, filed Dec. 31, 2009, Inventors: Jong-Mook Kim et al.
- File History of U.S. Appl. No. 11/957,170, filed Dec. 14, 2007, Inventors: Jong-Mook Kim et al.
- File History of U.S. Appl. No. 10/944,277, filed Sep. 20, 2004, Inventors: Jong-Mook Kim et al.
- File History of U.S. Appl. No. 12/908,765, filed Oct. 20, 2010, Inventors: Jong-Mook Kim et al.
- PCT International Search Report, PCT Application No. PCT/KR2003/000548, Sep. 5, 2003, 3 pages.
- Shi, E. et al., "Nonviral Gene Transfer of Hepatocyte Growth Factor Attenuates Neurologic Injury After Spinal Cord Ischemia in Rabbits," Cardiopulmonary Support and Physiology, The Journal of Thoracic and Cardiovascular Surgery, Oct. 2006, pp. 941-947, vol. 132, No. 4.
- Morishita, R. et al., "Safety Evaluation of Clinical Gene Therapy Using Hepatocyte Growth Factor to Treat Peripheral Arterial Disease," Hypertension, Aug. 2004, 13 pages.
- Shigematsu, H. et al., "Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Hepatocyte Growth Factor Plasmid for Critical Limb Ischemia," Gene Therapy, 2010, pp. 1152-1161, vol. 17.
- Kibbe, M.R. et al., "Safety and Efficacy of Plasmid DNA Expressing Two Isoforms of Hepatocyte Growth Factor in Patients with Critical Limb Ischemia," Gene Therapy, 2016, pp. 306-312, vol. 23.
- Henry, T.D. et al., "Safety of a Non-Viral Plasmid-Encoding Dual Isoforms of Hepatocyte Growth Factor in Critical Limb Ischemia Patients: A Phase I Study," Gene Therapy, 2011, pp. 788-794, vol. 18.
- Deng, et al., "Secretory Expression of the Deleted Variant of Human Hepatocyte Growth Factor (hdHGF) in *Pichia pastoris*," *Chinese Journal of Biochemistry and Molecular Biology*, 2001, 17:590-594, China Academic Journal Electronic Publishing House, Beijing, China.
- Kisselev, L., "Polypeptide Release Factors in Prokaryotes and Eukaryotes: Same Function, Different Structure," *Structure*, 2002, 10, pp. 8-9, Elsevier Science Ltd., Cambridge, Massachusetts, USA.
- Liu, Y., "The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization," *Gene* 215:159-169, Elsevier/North-Holland (1998).
- Miyazawa, K., et al., "Molecular Cloning and Sequence Analysis of cDNA for Human Hepatocyte Growth Factor," *Biochem. Biophys. Res. Commun.* 163:967-973, Academic Press (1989).
- Nakamura, T., et al., "Molecular cloning and expression of human hepatocyte growth factor," *Nature* 342:440-443, Nature Publishing Group (1989).
- NCBI Entrez, GenBank Database, Accession No. AC004960, "Homo sapiens PAC clone RP5-1098B1 from 7q11.23-q21, complete sequence," 51 pages (first available 1998).
- Ngo et al., In The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.
- Potrykus. Gene transfer to cereals: an assessment, Biotechnology, 1990, 8(6):535-542.
- Rubin, et al., "A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor," *Proc. Natl. Acad. Sci. USA*, 1991, 88:415-419, Proceedings of the National Academy of Sciences of the United States of America, 500 5th St., Washington, DC 20001.
- Seki, T., et al., "Isolation and Expression of cDNA for Different Forms of Hepatocyte Growth Factor from Human Leukocyte," *Biochem. Biophys. Res. Commun.* 172:321-327, Academic Press (1990).
- Seki, T., et al., "Organization of the human hepatocyte growth factor-encoding gene," *Gene* 102:213-219, Elsevier/North-Holland (1991).
- Shima, N., et al., "Hepatocyte Growth Factor and its Variant with a Deletion of Five Amino Acids are Distinguishable in their Biological Activity and Tertiary Structure," *Biochem. Biophys. Res. Commun.* 200:808-815, Academic Press (1994).
- Warnecke C. et al., "Efficient transcription of the human angiotensin II type 2 receptor gene requires intronic sequence elements," *Biochemical journal*, 1999, 340 (1), pp. 17-24, Portland Press, Colchester, Great Britain.
- Wishart et al., "A Single Mutation Converts a Novel Phosphotyrosine Binding into a Dual-Specificity Phosphatase," *Journal of Biological Chemistry*, 1995, 270 (45), pp. 26782-26785, American Society for Biochemistry and Molecular Biology, Bethesda, MD, USA.
- Witkowski et al., "Conversion of a A-Ketoacyl Synthase to a Malonyl Decarboxylase by Replacement of the Active-Site Cysteine with Glutamine," *Biochemistry*, 1999, 38 (36), pp. 11643-11650, American Chemical Society, Washington, DC, USA.
- Office Action for Co-pending U.S. Appl. No. 10/944,277, mailed Jan. 9, 2008.
- Office Action for Co-Pending U.S. Appl. No. 10/944,277, mailed Feb. 13, 2009.
- Notice of Allowance and Fees Due for Co-Pending U.S. Appl. No. 10/944,277, mailed May 29, 2009.
- Notice of Allowance and Fees Due for Co-Pending U.S. Appl. No. 10/944,277, mailed Oct. 23, 2009.
- Office Action for Co-pending U.S. Appl. No. 11/957,170, mailed Jan. 28, 2010.

* cited by examiner


FIG. 1

FIG. 2





FIG. 3







FIG. 4B


FIG. 5


FIG. 6


FIG. 7




FIG. 8

FIG. 9

FIG. 10





**HYBRID HEPATOCYTE GROWTH FACTOR
GENE HAVING HIGH EXPRESSION
EFFICIENCY OF TWO HETERO TYPES OF
HEPATOCYTE GROWTH FACTOR**

Matter enclosed in heavy brackets [] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue; a claim printed with strikethrough indicates that the claim was canceled, disclaimed, or held invalid by a prior post-patent action or proceeding.

[This application is a continuation] *The present application is a Reissue of U.S. Pat. No. 7,745,174, which issued on Jun. 29, 2010 from application Ser. No. 12/650,860, filed Dec. 31, 2009. U.S. application Ser. No. 12/650,860 is a divisional of U.S. application Ser. No. 10/944,277, filed Sep. 20, 2004, now U.S. Pat. No. 7,812,146, which is a continuation of International Application No. PCT/KR03/00548, filed Mar. 20, 2003, which claims priority benefit to Korean Appl. No. 10-2002-0015074, filed Mar. 20, 2002, each of which [are] is herein incorporated by reference in [their] its entirety.*

**REFERENCE TO A SEQUENCE LISTING
SUBMITTED ELECTRONICALLY**

The content of the electronically submitted sequence listing ("sequencelisting.ascii.txt", 29,879 bytes, created on Dec. 30, 2009) filed with the application is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a highly efficient hybrid Hepatocyte Growth Factor (HGF) gene which simultaneously expresses two heterotypes of HGF.

2. Related Art

The present invention relates to a hybrid HGF gene prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has higher expression efficiency than HGF cDNA and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF).

HGF is a heparin binding glycoprotein called a scatter factor. A gene encoding HGF is located at chromosome [721.1] 7q21.1 and comprises 18 exons and 17 introns, having the nucleotide sequence of SEQ ID NO: 1 (Seki T., et al., Gene 102:213-219 (1991)). A transcript of about 6 kb is transcribed from the HGF gene, and then, a polypeptide HGF precursor consisting of 728 amino acids is synthesized therefrom. Simultaneously, a polypeptide of dHGF precursor consisting of 723 amino acids is also synthesized by an alternative splicing of the HGF gene. The biologically inactive precursors may be converted into active forms of disulfide-linked heterodimer by protease in serum. In the heterodimers, the alpha chain having a high molecular weight forms four kringle domains and an N-terminal hairpin loop like a preactivated peptide region of plasminogen. The kringle domains of a triple disulfide-bonded loop structure consisting of about 80 amino acids may play an important role in protein-protein interaction. The low molecular weight beta chain forms an inactive serine protease-like domain. dHGF consisting 723 amino acids is a polypeptide

with deletion of five amino acids in the 1st kringle domain of the alpha chain, i.e., F, L, P, S and S.

It has been recently reported that both of HGF and dHGF have several biological functions, e.g., promoting the growth and morphogenesis of epithelial cell, melanocyte and endothelial cell. However, they are different in terms of immunological or biological properties.

For example, HGF shows about 20-fold, 10-fold and 2-fold higher activities than dHGF in promoting DNA synthesis in human umbilical cord venous endothelial cell, arterial smooth muscle cell and NSF-60 (murine myeloblast cell), respectively. dHGF shows about 3-fold and 2-fold higher activities than HGF in promoting DNA synthesis of LLC-PK1 (pig kidney epithelial cell), and OK (American opossum kidney epithelial cell) and mouse interstitial cell, respectively. HGF has a 70-fold higher solubility in PBS than dHGF. Several anti-dHGF monoclonal antibodies recognize only dHGF, but not HGF or a reduced form of dHGF, which implies structures of HGF and dHGF are different. Accordingly, the simultaneous synthesis of HGF and dHGF in vivo suggests that they biologically interact with each other (Shima, N. et al., Biochemical and Biophysical Research Communications 200:808-815 (1994)).

HGF secreted from mesoderm-derived cells has various biological functions, e.g., 1) inducing epithelial cells into a tubular structure; 2) stimulating vascularization from endothelial cells in vitro and in vivo; 3) regeneration of liver and kidney, owing to its anti-apoptosis activity; 4) organogenesis of kidney, ovary and testis; 5) controlling osteogenesis; 6) stimulating the growth and differentiation of erythroid hematopoietic precursor cells; and 7) axon sprouting of neurons (Stella, M. C. and Comoglio, P. M., The International Journal of Biochemistry & Cell Biology 31:1357-1362 (1999)). Based on these various functions, HGF or a gene encoding HGF may be developed as a therapeutic agent for treating ischemic or liver diseases. Actually, in vivo, the HGF may exist as either HGF or dHGF, and therefore, the coexpression of HGF and dHGF is important for maximizing the therapeutic effect. Accordingly, the present inventors have endeavored to develop a hybrid HGF gene which can simultaneously express HGF and dHGF with a high efficiency for gene therapy.

SUMMARY OF THE INVENTION

Accordingly, it is a primary object of the present invention to provide a hybrid HGF gene which simultaneously expresses two heterotypes of HGF.

In accordance with one aspect of the present invention, there is provide the hybrid HGF gene having an inherent or foreign intron is inserted between exons 4 and 5 of HGF cDNA.

It is another object of the present invention to provide a recombinant vector comprising the hybrid HGF gene and a microorganism transformed with the above vector.

It is a still further object of the present invention to provide a pharmaceutical composition for treating or preventing ischemic or liver diseases, which comprises the HGF gene.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other objects and features of the present invention will become apparent from the following description of the invention, when taken in conjunction with the accompanying drawings which respectively show:

FIG. 1: a schematic diagram of HGF-X prototype illustrating the positions of the gene fragments,

FIG. 2: a process for cloning gene fragments from HepG2 genomic DNA,

FIG. 3: a process for cloning gene fragments from human placenta cDNA,

FIGS. 4A and 4B: processes for preparing expression vectors pCK-HGF-X,

FIG. 5: a process for preparing expression vectors pCK-cHGF and pCK-dHGF,

FIG. 6: a process for preparing expression vectors pCP-HGF-X family,

FIG. 7: a process for preparing expression vectors pCP-cHGF and pCP-dHGF,

FIG. 8: gene expression levels of pCP-cHGF, pCP-dHGF and pCP-HGF-X.

FIG. 9: gene expression patterns of pCP-cHGF, pCP-dHGF and pCP-HGF-X observed by electrophoresis on 12% polyacrylamide gel,

FIG. 10: gene expression levels of pCP-cHGF, pCP-dHGF and pCP-HGF-X7, in vivo,

FIG. 11: cerebral angiogenesis of two groups of rabbits which were subject to administrating pCP and pCP-HGF-X7, respectively,

DETAILED DESCRIPTION OF THE INVENTION

The hybrid Hepatocyte Growth Factor (HGF) gene of the present invention comprises cDNA corresponding to the exons 1 to 18, and an inherent or foreign intron inserted between exons 4 and 5 of the cDNA. The intron comprises a fragment of the inherent intro or a recombinant sequence.

An embodiment of the hybrid HGF gene of the present invention comprising the inherent intron is 7113 bp long and has the nucleotide sequence of SEQ ID NO: 2. The hybrid HGF gene simultaneously expresses both HGF and dHGF, and has higher expression efficiency than HGF cDNA.

Codon degeneracy enables the hybrid HGF gene of the present invention to be modified or changed in the coding and/or non-coding region without altering the amino acid sequence of the protein and the expression of the gene. Accordingly, polynucleotides which is substantially identical to the hybrid HGF gene of SEQ ID NO:2, and the fragments thereof fall within the scope of the invention. "Substantially identical" means that the sequence homology is not less than 80%, preferably not less than 90%, and more preferably not less than 95%.

A hybrid HGF gene may comprise a fragment of inherent intron optionally having a small recombinant sequence inserted thereinto between exons 4 and 5 of HGF cDNA. Herein, such a hybrid HGF gene comprising a fragment of inherent intron designates "HGF-X". HGFX-6, HGF-X7 and HGF-X8 having the nucleotide sequence of SEQ ID Nos: 19 to 21, respectively, are preferred.

The hybrid HGF gene of the present invention is synthesized and inserted into an expression vector, according to the known genetic engineering methods. Then, the vector can be introduced into an appropriate host cells such as *E. coli* and yeast. For example, *Escherichia coli* Top10F' may be transfected with HGF-X7 gene of the present invention. *Escherichia coli* Top10F' pCK-HGFX7 and *Escherichia coli* Top10F' pCP-HGFX7 then obtained were deposited as the accession numbers KCCM-10361 and KCCM-10362, respectively, on Mar. 12, 2002.

By using the transformed cells, the gene of the present invention and the protein encoded thereby may be produced on a large scale.

The vector of the present invention may selectively comprise sequence(s) for regulating gene expression such as promoter or terminator, self-replication sequence and secretory signal, depending on host cells.

Further, the present invention comprises a pharmaceutical composition for treating or preventing ischemic and liver diseases, which comprises the hybrid HGF gene or the vector comprising the gene as an active ingredient. Preferably, the composition is formulated for injection.

The composition of the present invention may further comprise pharmaceutically acceptable carriers. Any of the conventional procedures in the pharmaceutical field may be used to prepare oral formulations such as tablets, capsules, pills, granules, suspensions and solutions; injection formulations such as solutions, suspensions, or dried powders that may be mixed with distilled water before injection; locally-applicable formulations such as ointments, creams and lotions; and other formulations.

Carriers generally used in the pharmaceutical field may be employed in the composition of the present invention. For example, orally-administered formulations may include binders, emulsifiers, disintegrating agents, excipients, solubilizing agents, dispersing agents, stabilizing agents, suspending agents, coloring agents or spicery. Injection formulations may comprise preservatives, unagonizing agents, solubilizing agents or stabilizing agents. Preparation for local administration may contain bases, excipients, lubricants or preservatives. Any of the suitable formulations known in the art (Remington's Pharmaceutical Science [the new edition], Mack Publishing Company, Eaton Pa.) may be used in the present invention.

The inventive composition can be clinically administered as various oral and parenteral formulations. A suitable formulation may be prepared using such excipients as additives, enhancers, binders, wetting agents, disintegrating agents and surfactants, or diluents. Solid formulations for oral administration include pills, tablets, dusting powder, granules and capsules. Those solid formulations may be prepared by mixing one or more excipients, e.g. starch, calcium carbonate, sucrose, lactose and gelatin with dibenzylbutyrylacton lignan derivatives. Also, lubricants such as magnesium stearate and talc may be included in the present formulation. Liquid formulations for oral administration include suspension, solution, emulsion and syrup. Those formulations may contain wetting agents, sweeteners, aromatics and preservatives, in addition to general simple diluents such as water and liquid paraffin. Formulations for parenteral administration include sterilized aqueous solution, suspension, emulsion, freeze-dried alternative treatment and suppositories. Water-insoluble excipients and suspending agents comprise vegetable fats such as propylene glycol, polyethylene glycol and olive oil, and injectable esters such as ethyl oleate. Witepsol®, Macrogol®, Tween® 61, cacao fats, laurin fats and glycerogelatins may be used as bases of suppositories.

The inventive composition may be administered orally or via parenteral routes such as intravenous, intramuscular, subcutaneous, intraabdominal, sternal and arterial injection or infusion, or topically through rectal, intranasal, inhalational or intraocular administration.

It should be understood that the typical daily dose of composition of the present invention ought to be determined in light of various relevant factors including the conditions to be treated, the chosen route of administration, the age, sex

and body weight of the individual patient, and the severity of the patient's symptom, and can be administrated in a single dose or in divided dose. Therefore, the daily dose should not be construed as a limitation to the scope of the invention in any way.

The following Examples are given for the purpose of illustration only, and are not intended to limit the scope of the invention.

EXAMPLE 1

Preparation of Hybrid Gene Constructs Encoding Human HGF

(1) Cloning of HGF Gene Fragments Obtained from Genomic DNA

Human HepG2 cells (ATCC Accession NO: HB-8065) were suspended in TES buffer (10 mM Tris-HCl; 1 mM EDTA; 0.7% SDS) and treated with 400 µg/ml of proteinase K at 50° C. for 1 hour. Subsequently, genomic DNA was extracted from the cell suspension by phenol/chloroform extraction and ethanol precipitation according to the conventional method in the art.

In the PCR amplification, the extracted genomic DNA was employed as a template DNA. As primer pairs, the synthetic nucleotides of SEQ ID NOs: 3 and 4 were employed to obtain DNA fragments containing: HGF gene fragment 2 (HGF-F2), SEQ ID NOs: 3 and 5; HGF-F3, SEQ ID NOs: 6 and 7; HGF-F5, SEQ ID NOs: 8 and 7; HGF-F7, SEQ ID NOs: 9 and 7; HGF-F8, SEQ ID NOs: 10 and 7; HGF-F6, respectively (FIG. 1). The PCR amplification mixture was prepared by mixing 1 µl of template DNA, 1 µl each of primer (10 pmol/µl), 10 µl of dNTP (10 mM), 3.5 unit of Expand High Fidelity enzyme (Gibco BRL, USA) and 10 µl of enzyme buffer solution and adjusted to a final volume of 100 µl with distilled water. 30 cycles of the PCR amplification was carried out, each cycle consisting of 1 min at 94° C., 1 min at 55° C. and 30 sec at 72° C. The primers used herein and the amplified gene fragments obtained therefrom are shown in Table 1.

TABLE 1

5' primer	3' primer	Amplified fragment
gHGF3 (SEQ ID NO: 3)	gHGF4 (SEQ ID NO: 4)	HGF gene fragment 2 (HGF-F2)
gHGF3 (SEQ ID NO: 3)	gHGF10 (SEQ ID NO: 5)	HGF gene fragment 3 (HGF-F3)
gHGF5 (SEQ ID NO: 6)	gHGF7 (SEQ ID NO: 7)	HGF gene fragment 5 (HGF-F5)
gHGF12 (SEQ ID NO: 8)	gHGF7 (SEQ ID NO: 7)	HGF gene fragment 7 (HGF-F7)
gHGF13 (SEQ ID NO: 9)	gHGF7 (SEQ ID NO: 7)	HGF gene fragment 8 (HGF-F8)
gHGF6 (SEQ ID NO: 10)	gHGF7 (SEQ ID NO: 7)	HGF gene fragment 6 (HGF-F6)

The amplified HGF-F2 comprised the sequence ranging from 392 to 2247 of human HGF cDNA prototype (HGF-X1; composed of exons 1 to 4-intron 4-exons 5 to 18) of SEQ ID NO: 2; HGF-F3, the sequence ranging from 392 to 727; HGF-F5, the sequence ranging from 2229 to 5471; HGF-F6, the sequence ranging from 5117 to 5471; HGF-F7, the sequence ranging from 3168 to 5471; and HGF-F8, the sequence ranging from 4168 to 5471.

The amplified HGF gene fragments were each inserted into the multiple cloning site of pGEM-T easy vector (Promega, WI, USA) to obtain pGEM-T easy-HGF-F2,

pGEM-T easy-HGF-F3, pGEM-T easy-HGF-F5, pGEM-T easy-HGF-F6, pGEM-T easy-HGF-F7 and pGEM-T easy-HGF-F8, respectively (FIG. 2). The nucleotide sequences of the amplified HGF gene fragments were confirmed by a sequence analysis.

(2) Cloning of HGF Gene Fragments Obtained from cDNA

In the PCR amplification, human placenta cDNA (Clontech, CA, USA) was employed as a template DNA under the same condition as described in Example 1. As primer pairs, the synthetic oligonucleotides of SEQ ID NOs: 11 and 12, and SEQ ID NOs: 13 and 14 were employed to obtain DNA fragments containing HGF-F1 and HGF-F4, respectively. Further, DNA fragments containing cDNAs of HGF gene (cHGF) and deleted HGF gene (dHGF) were amplified by PCR using synthetic oligonucleotides of SEQ ID NOs: 15 and 16 as a primer pair, respectively. dHGF is a HGF gene with deletion of 5 base sequences.

The primers used herein and the amplified gene fragments obtained therefrom are shown in Table 2.

TABLE 2

5' primer	3' primer	Amplified fragment
gHGF1 (SEQ ID NO: 11)	gHGF2 (SEQ ID NO: 12)	HGF gene fragment 1 (HGF-F1)
gHGF8 (SEQ ID NO: 13)	gHGF9 (SEQ ID NO: 14)	HGF gene fragment 4 (HGF-F4)
cHGF5 (SEQ ID NO: 15)	cHGF3 (SEQ ID NO: 16)	HGF gene cDNA (cHGF)
		dHGF gene cDNA (dHGF)

The amplified HGF-F1 and HGF-F4 comprised the nucleotide sequences ranging from 1 to 402 and from 6533 to 7113 of SEQ ID NO: 2 of human HGF cDNA prototype, respectively. HGF gene cDNA comprised the nucleotide sequence ranging from 1 to 2184 of SEQ ID NO: 1 of human HGF gene, and dHGF gene cDNA has the same sequence as HGF gene cDNA except for the deletion of the sequence ranging from 483 to 495.

The amplified fragments of HGF gene were each inserted into the multiple cloning site of pGEM-T easy vector (Promega, WI, USA) to obtain pGEM-T easy-HGF-F1, pGEM-T easy-HGF-F4, pGEM-T easy-cHGF and pGEM-T easy-dHGF, respectively (FIG. 3). The nucleotide sequences of the human HGF gene fragments, HGF gene cDNA and dHGF gene cDNA were confirmed by sequence analyses.

(3) Preparation of Hybrid HGF Gene Constructs

Hybrid HGF gene constructs of genomic DNA and cDNA were prepared by combining the fragments of HGF gene cloned in steps (1) and (2) as follows (FIGS. 4A and 4B).

Plasmid pGEM-T-easy-HGF-F1 was treated with HindIII/BamHI to obtain HGF-F1. Plasmid pCK (see PCT International Publication NO: WO/0040737) was treated with HindIII/BamHI, and HGF-F1 was inserted thereinto to obtain pCK-F1. And then, plasmids pGEM-T-easy-HGF-F2 and pGEM-T-easy-HGF-F3 were treated with MluI/BamHI to obtain HGF-F2 and HGF-F3, respectively. pCK-1 was treated with MluI/BamHI, and then HGF-F2 and HGF-F3 were inserted thereinto to obtain pCK-F12M and pCKF13M. The MluI restriction site of vectors pCK-F12M and pCK-F13M was substituted with an HgaI restriction site by employing a site-directed mutagenesis kit (Stratagene, CA, USA) to obtain pCK-F12 and pCK-F13, respectively.

Further, plasmid pGEM-T-easy-HGF-F4 was treated with BamHI/XbaI to obtain HGF-F4. pCK-F12 and pCK-F13 were treated with BamHI/XbaI, and HGF-F4 was inserted

thereinto to obtain pCK-F124 and pCK-F134, respectively. And then, plasmids pGEM-T-easy-HGF-F5, pGEM-T-easy-HGF-F6, pGEM-T-easy-HGF-F7 and pGEM-T-easy-HGF-F8 were treated with BamHI/XhoI to obtain HGF-F5, HGF-F6, HGF-F7 and HGF-F8, respectively. pCK-F124 and pCK-F134 were treated with BamHI/XhoI, and then HGF-F5, HGF-F6, HGF-F7 and HGF-F8 were inserted thereinto to obtain pCK-F1254 and pCK-F1264, pCK-F1274, pCK-F1284, pCK-F1354, pCK-F1364, pCK-F1374 and pCK-F1384, respectively.

And then, pGEM-T easy-cHGF was treated with XhoI to obtain cDNA fragment of HGF gene (HGF-XhoI) of about 1100 bp. Then, HGF-XhoI was inserted into pCK-F1254, pCK-F1264, pCK-F1274, pCK-F1284, pCK-F1354, pCK-F1364, pCK-F1374 and pCK-F1384 to obtain pCK-HGF-X1, pCK-HGF-X2, pCK-HGF-X3, pCK-HGF-X4, pCK-HGF-X5, pCK-HGF-X6, pCK-HGF-X7 and pCK-HGF-X8, respectively. On the other hand, pGEM-T easy-cHGF and pGEM-T easy-dHGF were treated with BamHI to obtain HGF gene cDNA and dHGF gene cDNA. Then, HGF gene cDNA and dHGF gene cDNA were inserted into the BamHI restriction site of pCK to obtain pCK-cHGF and pCK-dHGF, respectively (FIG. 5).

(4) Preparation of an Expression Vector Containing a Hybrid HGF Gene Construct

Plasmid pcDNA3.1 (Invitrogen, USA) was digested with NdeI, treated with the Klenow fragment to build blunt ends, and then digested with NheI to obtain a DNA fragment containing human cytomegalovirus promoter. Plasmids pCK-HGF-X1, pCK-HGF-X2, pCK-HGF-X3, pCK-HGF-X4, pCK-HGF-X5, pCK-HGF-X6, pCK-HGF-X7 and pCK-HGF-X8 were digested with SnaBI, treated with the Klenow fragment to make blunt ends and digested with NheI, and then the above DNA fragment containing human cytomegalovirus promoter was inserted thereinto to obtain pCP-HGF-X1, pCP-HGF-X2, pCP-HGF-X3, pCP-HGF-X4, pCP-HGF-X5, pCP-HGF-X6, pCP-HGF-X7 and pCP-HGF-X8, respectively (FIG. 6).

Plasmid pcDNA3.1 (Invitrogen, USA) was digested with NheI, treated with the Klenow fragment to make blunt ends and digested with NdeI to obtain the DNA fragment containing human cytomegalovirus promoter. pCK-cHGF and pCK-dHGF were digested with MluI, treated with the Klenow fragment to make blunt ends and digested with NdeI, and then the above DNA fragment containing human cytomegalovirus promoter was inserted thereinto to obtain pCP-cHGF and pCP-dHGF, respectively (FIG. 7).

EXAMPLE 2

Examination of the Expression Efficiency of Hybrid HGF Gene Construct and the Coexpression of HGF/dHGF

Studies was conducted to examine whether the hybrid HGF gene constructs (HGF-X1 to HGF-X8) obtained in Example 1 can simultaneously express HGF and dHGF and whether there is any difference in the gene expression level between hybrid HGF gene constructs and HGF cDNA.

(1) Gene Expression Efficiency

First, 5 µg of pCP-HGF-X2, pCP-HGF-X3, pCP-HGF-X6, pCP-HGF-X7 and pCP-HGF-X8 were transfected into 5×10^6 cells of 293 cell (ATCC CRL 1573) together with 0.5 µg of DONAI-LacZ (TAKARA SHUZO, Japan) DNA using FuGENE6 (Gibco BRL, MD, USA), according to the manufacturer's instructions. At this time, 5 µg each of pCP-cHGF and pCP-dHGF were used as controls, and DONAI-LacZ

DNA was used to calibrate the infection efficiency. 3 hours after transfection, cells were re-fed with a fresh medium and further cultured for 48 hours. The culture solution thus obtained was divided into two parts. One part of the 293 cell culture solution was subjected to RNA extraction, and the other, to measurement of LacZ activity. The LacZ activity was measured using an activity measuring kit (Stratagene, CA, USA) according to the manufacturer's instructions.

In order to compare the gene expression levels, the amount of HGF in the cell culture was measured by an enzyme-linked immunosorbent assay kit (ELISA, R&D System, MN, USA). After calibrating the infection efficiency by the measured LacZ activity, the expression level of HGF-X gene was found to be from 20 to 150-fold higher than those of HGF cDNA and dHGF cDNA (FIG. 8). HGF-X7, in particular, showed the highest gene expression level.

(2) Coexpression of HGF and dHGF

In order to examine coexpression of HGF and dHGF from hybrid HGF gene constructs, total cellular RNAs were extracted from the transfected 293 cells using the Trizol method (Trizol; Gibco BRL, USA) and subjected to RT-PCR to obtain cDNA. Then, using cDNA as a template DNA, PCR amplification was carried out using synthetic oligonucleotides of SEQ ID NOs: 17 and 18 as a primer pair. The PCR amplification mixture was prepared by mixing 1 µl of the template DNA, 1 µl each of the primer (10 pmol/µl), 10 µl of dNTP (10 mM), 3.5 unit of Taq polymerase (TAKARA SHUZO, Japan) and 10 µl of enzyme buffer solution and adjusted to a final volume of 100 µl with distilled water. 30 cycles of PCR amplification was conducted, each cycle consisting of 1 min at 94° C., 1 min at 55° C., and 90 sec at 72° C.

The amplified PCR products corresponded to the boundary region between exons 4 and 5 of HGF gene; HGF gene cDNA of 142 by and dHGF gene cDNA of 127 bp, respectively. With no splicing, the PCR product of at least 1 kb in length was amplified; and if alternative splicing occurred, HGF gene cDNA of 142 bp and dHGF gene cDNA of 127 by were simultaneously synthesized and amplified. The amplified PCR products were distinguished by electrophoresis on a 12% polyacrylamide gel.

As shown in FIG. 9, while the bands of 142 by and 127 by were detected in the lanes loading HGF gene cDNA and dHGF gene cDNA, respectively, both bands of 142 by and 127 by were detected in the lanes loading HGF-X. The above results suggest that HGF and dHGF are simultaneously expressed from hybrid HGF-X gene constructs of the present invention.

EXAMPLE 3

Comparison of Expression Levels of HGF-X7, HGF Gene cDNA and dHGF Gene cDNA (In Vivo)

100 µg each of pCP-HGF-X7, pCP-cHGF and pCP-dHGF were injected into the [anterior] anterior tibial muscle of the hind limb of mice with an insulin syringe. After 5 days, the mice were sacrificed and the muscles around the injection spot were removed and smashed in a protein extraction buffer (25 mM Tris-HCl (pH 7.4), 50 mM NaCl, 0.5% Na-deoxycholate, 2% NP-40, 0.2% SDS) to separate total proteins. The amount of the total proteins was measured with a DC protein analysis kit (Bio-Rad Laboratories, CA,

USA) and the amount of expressed HGF was determined with an ELISA kit (R&D System) according to the manufacturer's instruction.

As can be seen from the result shown in FIG. 10, the amount of HGF expressed from HGF-X7 is 250-fold higher than that from HGF gene cDNA or dHGF gene cDNA.

Together with the result of the experiment of Example 2 (in vivo), this result demonstrates that the expression efficiency of HGF-X gene is much superior to those of HGF gene cDNA or dHGF gene cDNA.

EXAMPLE 4

Gene Therapy Employing HGF-X7 in a Rabbit Ischemic Hind Limb Model

In order to examine whether HGF-X7 gene is effective in the treatment of ischemic hind limb disease, gene therapy was carried out on a rabbit ischemic hind limb model as follows.

A rabbit ischemic hind limb model, which is a standard animal model for the ischemic limb disease, was prepared by the method described by Takeshita et al., Journal of Clinical Investigation 93:662 (1994). At the day before operation (day 0), each of 30 white rabbits from New Zealand (male, from 3.8 to 4.2 kg) was intramuscularly injected with 5 mg/kg of xylazine and, then, anesthetized by an intramuscular injection of 50 mg/kg of ketamine. Subsequently, the

left femoral region of the rabbit was incised and all branches of the femoral artery were separated and tied. The region from the proximal part to the branching point of the saphenous and popliteal arteries was incised to prepare the model. After the operation, 15 mg/kg/day of cefazolin was injected intramuscularly for 5 days and 0.3 mg/day of morphine, for 10 days. 10 days after the operation (day 10), angiography was carried out for the left hind limb where the ischemia was induced, and the degree of arteriogenesis was recorded as a basal level. The rabbits were randomly divided into two groups and injected at four sites in the femoral muscle with 500 µg of plasmid pCP-HGF-X7 (experimental group) or 500 µg of plasmid pCP (control), respectively. 40 days after the operation (day 40), angiography was carried out again for the left hind limb and the degree of arteriogenesis at the arteriole level was determined and compared to that of day 10.

As can be seen from the result in FIG. 11, the degree of angiogenesis was significantly enhanced in the experimental group administered with pCP-HGF-X7 as compared with the pCP-administered control group.

This result demonstrates that HGF-X7 gene can be effectively used in the gene therapy of an ischemic disease.

While the invention has been described with respect to the above specific embodiments, it should be recognized that various modifications and changes may be made to the invention by those skilled in the art which also fall within the scope of the invention as defined by the appended claims.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 21

<210> SEQ ID NO 1

<211> LENGTH: 2187

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 1

atgtgggtga	ccaaactcct	gccagccctg	ctgctgcagc	atgtcctcct	gcatctcctc	60
ctgctccccca	tcgccatccc	ctatgcagag	ggacaaagga	aaagaagaaa	tacaattcat	120
gaattcaaaa	aatcagcaaa	gactacccta	atcaaaatag	atccagcact	gaagataaaa	180
accaaaaaaag	tgaatactgc	agaccaatgt	gctaatacgat	gtactaggaa	taaaggactt	240
ccattcaatt	gcaaggcttt	tgttttgat	aaagcaagaa	aacaatgcct	ctgggtcccc	300
ttcaatagca	tgtcaagtgg	agtaaaaaaaaa	gaatttggcc	atgaatttga	cctctatgaa	360
aacaaagact	acattagaaa	ctgcattcatt	ggtaaaggac	gcagctacaa	gggaacagta	420
tctatcaacta	agagtggcat	caaatgtcag	ccctggagtt	ccatgatacc	acacgaacac	480
agcttttgc	cttcgagcta	tcgggtaaa	gacctacagg	aaaactactg	tcgaaatcct	540
cgaggggaag	aaggggacc	ctgggttttc	acaagcaatc	cagaggtacg	ctacgaagtc	600
tgtgacattc	ctcagtgttc	agaagttgaa	tgcattgac	gcaatgggga	gagttatcga	660
ggtctcatgg	atcatacaga	atcaggcaag	atttgcagc	gctggatca	tcagacacca	720
caccggcaca	aattcttgcc	tgaaagatat	cccgacaagg	gctttgatga	taattattgc	780
cgcaatcccg	atggccagcc	gaggccatgg	tgctatactc	ttgaccctca	cacccgctgg	840
gagtactgtg	caattaaaac	atgcgtgac	aatactatga	atgacactga	tgttcccttg	900
gaaacaactg	aatgcattcca	aggtcaagga	gaaggctaca	ggggcactgt	caataccatt	960
tggaatggaa	ttccatgtca	gcgttggat	tctcagtatc	ctcacgagca	tgacatgact	1020

US RE48,404 E

11**12**

- continued

cctgaaaatt tcaagtcaa ggacctacga gaaaattact gccgaaatcc agatgggtct	1080
gaatcaccct ggtgtttac cactgatcca aacatccgag ttggctactg ctcccaaatt	1140
ccaaactgtg atatgtcaca tggacaagat tggtatcgta ggaatggcaa aaattatacg	1200
ggcaacttat cccaaacaag atctggacta acatgttcaa tgtggacaa gaacatggaa	1260
gacttacatc gtcatatctt ctggAACCA gatgcAGTA agctGAATGA gaattactgc	1320
cgaaatccag atgatgatgc tcatggaccc tggtgctaca cgggaaatcc actcattcct	1380
tgggattatt gccctatttc tcgttgtgaa ggtgataCCA cacctacaat agtcaattta	1440
gaccatcccc taatatctt tgccAAAACG aaacaattgc gagttgtaaa tgggattcca	1500
acacgaacaa acataggatg gatggtagt ttgagatACA gaaataAAACA tatctgcggA	1560
ggatcattGA taaaggAGAG ttgggttctt actgcacgac agtgtttccc ttctcgagac	1620
ttgaaagatt atgaagctt gcttggatt catgatgtcc acggaAGAGG agatgagaaa	1680
tgcaaacagg ttctcaatgt ttccCAGCTG gtatATGGCC ctgaaggatc agatctggTT	1740
ttaatgaAGC ttGCCAGGCC tgctgtcctg gatgattttg ttagtacgt tgatttacct	1800
aattatggat gcacaattcc tgAAAAGACC agttgcAGTG tttatggctg gggctacact	1860
ggattgatca actatgatgg cctattacga gtggcacatc tctatataat gggAAATGAG	1920
aaatgcAGCC agcatcatcg agggAAAGGTG actctGAATG agtctgAAAT atgtgtCTGGG	1980
gctgAAAAGA ttggatcagg accatgtgag ggggattatg gtggcccact tgTTTGTGAG	2040
caacataAAA tgagaatgtt tcttgggtgc attgttcctg gtcgtggatg tgccattcca	2100
aatcgtcctg gtatTTTGT ccgagtagca tattatgCAA aatggatACA caAAATTATT	2160
ttaacatata aggtaccaca gtcataG	2187

<210> SEQ_ID NO 2

<211> LENGTH: 7113

<212> TYPE: DNA

<213> ORGANISM: Homo sapiens

<400> SEQUENCE: 2

atgtgggtga ccaaactcct gccagccctg ctgctgcAGC atgtcctcct gcatctccTC	60
ctgctccccca tcGCCATCCC ctatgcAGAG ggacAAAGGA aaAGAAAGAAA tacaattcat	120
gaattcaAAA aatcAGCAAA gactacccta atcaAAATAG atccAGCAct gaAGATAAAA	180
accAAAAAAAG tgaataACTGC agaccaATGT gctaATAGAT gtactAGGAA taaAGGACTT	240
ccattcactt gcaaggcttt tgTTTTGAT aaAGCAAGAA aacaATGCCT ctggTTCCCC	300
ttcaatAGCA tgcAAGTGG AGTGAaaaaaa gaATTGGCC atgaATTGA CCTCTATGAA	360
aacAAAGACT acattAGAAA ctgcATCATT ggtAAAGGAC gcAGCTACAA gggAACAGTA	420
tctatcActA agAGTGGCAT caaatgtcAG ccctggAGTT ccatgatACC acacgAACAC	480
aggtAAAGAAC agtAtGAAGA AAAGAGATGA agcctctgTC tttttACAT gttAACAGTC	540
tcatattAGT cttcAGAAAT aattctACAA tcctAAATA ACTTAGCCAA CTTGCTGAAT	600
tgtattACGG caAGGTTAT atgaattCAT gactgatATT tagCAAATGA ttaattaATA	660
tgttaATAAA atgtAGCCAA aacaATATCT tacCTTAATG cctcaATTG tagATCTCGG	720
tatttGTAATG ataataACGT aaACTTCGTT taaaAGGATT CTTCTTCCTG TCTTTGAGAA	780
agtacggcac tgcAGGGGG gagAGGTTGA ttgtgAAAAA tcAGAGGTAG atgagaATCT	840
tactgaggGC tgaggGTTCT ttaacCTTGG tggatCTCAA cattggTTGC acattAAAT	900

- continued

cacctgctgc aagcccttga cgaatcttac tttagaagatg acaacacaga acaattaaat	960
cagaatctct ggggagaata gggcaccagt attttttag gtcaccat gattccaaag	1020
tgcagccaaa tttgagaacc actgctaaaa gctcaagctt cagattgacc agctttcca	1080
tctcacctat cgccctaaaga ccaaatttga taaatgtgtt cattacgaca gatgggtact	1140
atttaaagat gagtaaacac aatatactta ggctcgtag actgagagtt ttaatcatca	1200
ctgaggaaaa acatagatata ctaatactga ctggagtatt agtcaaggct tatttcacac	1260
acaattttat cagaaaccaa agtagttaa aacagcttc cccttattag taatgcattg	1320
gagggtttac tttaccatgt acctgctga gcactgtacc ttgttaatct catttacttg	1380
taatgagaac cacacagcgg gtagtttat tggttctatt ttacctacat gacaaaactg	1440
aagcataaaa acacttagta agtttcagt gtcacgacacta actaggaagt gacatggcca	1500
gaatataagc ccagtcacca tcactctata acctgcttca ttaacaactt cagggcatga	1560
cacatttggc cggtcagtag aaccatgct gtgatttgg tttgcagtgg tggtgatgac	1620
tgccttggc aatccacttt ttattctatt ccattttggg gacacaattc tgcaagatga	1680
ttcttcatta ggaaacagag atgagttatt gaccaacaca gaaagaaaaa gagtttgg	1740
ctccacactg ggattaaacc tatgatcttgc cctaattaa cactagctg taagtgtcca	1800
agctgatcat ctctacaaca tttcaataac agaaaacaac aattttcaaa attagttact	1860
tacaattatg tagaaatgcc tctaaaacac agtattttcc ttatattaca aaaacaaaaa	1920
ttataattgg ttttgcctc ttttgagagt ttgcattgg tgactccctg catagtgaag	1980
aaaacatttt attaagtag atggatctaa gttttcatg aacaaaggaa tgacatttga	2040
aatcaatcct accctagtc aggagaatgc attagattaa cctagtagag gtcttatttc	2100
accctgagtt ttctatgatc gtgattctct gctggaggag taattgtgaa atagatctct	2160
ctggaaactg gcttcctagt ccaatcagct cttttaccaa tgaacacttc cttgtgatata	2220
agatgtttat ggccgagagg atccagtata ttaataaaaat cccttttgtt attcaatgag	2280
ggaaacacat aattttcatc aattagcgc ttattggaaat atctgcatga tggtttaaca	2340
cttttaagtg ttgactaaag attaatttttca cagaaaaatag aaaaagaaaat atgtttctgt	2400
ctggaggaat gatttttgt tgaccctaa attgaaatat ttacttagtg gcttaatggaa	2460
aagatgatga aagatgatga aattatgtt gaagcttaac tagaaaatca ggtgacactga	2520
tatctacatc tgcattccccc attggccacc cagcattcat taatgaatca gatgatggaa	2580
tagatcaagt ttccttagaa cacagtgaat attaaaagaa aacaaaggaa gcctagcacc	2640
tagaaagacct agtttatatt tcaaagtata tttggatgtt acccaatttt aaacatttcc	2700
tcacttgcctc ctcttaaagc cttgccaaca gcaaggacag agaacaaaaa atagtgtata	2760
tatgaataaa tgcttattttc agaatctgct gactggcaca tgctttgtgt gtaatgggtt	2820
ctcataaaaca cttgttgaat gaacacacat aagtgaaaga gcatggctag gcttcatccc	2880
ttggtcaat atgggggtgct aaagaaaaagc aggggaaata cattgggaca ctaacaaaaa	2940
aaaacagtta atttaggtaa aagataaaaat acaccacaga atgaagaaaa gagatgaccc	3000
agactgctct ttaaccttca tgtccttagag aggttttgc tatgaattgc attcagaatt	3060
gtggaaagga gccccatcttt tcttttgcatt ttgattttat taactccat gggggattt	3120
tattcgtgtt ttggccatata ctacttttgc tttctacatt attctctttt cttttctacc	3180
tgtatttgc ctaataaaatt gttgactttat taatttacta cttcctcaca gctttttttt	3240
ggctttacaa atccactgga aaggatatacg ggtgtatcac tttgtgtatt tcgggtgtca	3300

- continued

tgttagagg ggacaaaaat cctctctcaa actataaata ttgagtattt gtgtattgaa	3360
cattgctat aactactagg ttttttaaat aatcttaata tataaaatga tatagaaaaa	3420
ggaaaattat agttcgatt attcatctaa gtgaagagat taaaacccag ggagtaata	3480
aattgtctaa ggactaaggt tgtatactat ttaggtgata gatatgggc aaccgtatgg	3540
gttttatgt taacaaataa acttctcacc actctaccat atcaactttt ccataaaaaga	3600
gagctatagt attcttgct taaataaatt tgattagtgc atgacttctt gaaaacataat	3660
aaagcaaaag tcacatttga ttctatcaga aaagtgagta agccatggcc caaacaaaag	3720
atgcattaaa atattctgga atgatggagc taaaagtaag aaaaatgact ttttaaaaaa	3780
gtttactgtt aggaattgtt aaattatgct gaattttagt tgcattataa ttttgcag	3840
tcatacggtc tgacaacctg tcttatttct atttccccat atgaggaatg ctgttaagt	3900
atggatatta actattacta cttagatgca ttgaagttgc ataatatgga taatacttca	3960
ctggttccct gaaaatgtt agttagtaat aagtcttta cactattgt tttgtccaat	4020
aatttatatt ttctgaagac ttaactctag aatacactca tgtcaaaatg aaagaatttc	4080
attgcaaaat attgcttggt acatgacgca tacctgtatt tgtttgcgtt cacaacatga	4140
aaaatgatgg tttatttagaa gtttcattgg gtaggaaaca cattgaatg gtatttacta	4200
agatactaaa atccttggac ttcactctaa tttagtgcc atttagaact caaggtctca	4260
gtaaaatgtt aaataaagcc tgttaacaaa acacaagctg aatattaaaa atgtaactgg	4320
atttcaaaag aaatgtttac tggatttacc tgttagatgta tatttttat tatgatctt	4380
tgtgtaaagt ctggcagaca aatgcaatat ctaattgtt agtccaatat cacaagcagt	4440
acaaaaagtat aaaaaagact tggcctttc taatgttta aaatacttta tgctggtaat	4500
aacactaaga gtagggcact agaaatttttta agtgaagata atgtgttgc gttactgcac	4560
tcaatggctt actattataa accaaaactg ggatcaactaa gctccagtca gtcaaaatga	4620
tcaaaaattat tgaagagaat aagcaattct gttctttatt aggacacagt agatacagac	4680
tacaaagtgg agtgtgctt ataagaggta gcatttttta agtgtcaatt actctattat	4740
cccttggagc ttctcaaaat aaccatataa ggtgttaagat gttaaagggtt atggttcac	4800
tcagtcaca ggtaaagctt taggtgaga gaagctaat tacttactgg ggtctcacag	4860
taagaaatgt agctgaagtt tcagcccaga tttactgga ttctggcctc tttattcatg	4920
ttacttcattt aatctgtttc tcaattgtgc agaaaaaagg gggctattta taagaaaagc	4980
aataaacaaa caagtaatga tctcaaataa gtaatgcaag aaatagtgag atttcaaaat	5040
cagtggcagc gatttctcag ttctgtccta agtggccttgc ctcaatcacc tgctatctt	5100
tagtggagct ttgaaattat gtttcagaca acttcgattc agttctagaa tgtttgactc	5160
agcaaattca caggctcatc tttctaactt gatggtaat atggaaattc agctaaatgg	5220
atgttaataa aattcaaacg ttttaaggac agatgaaaat gacagaattt taaggtaaaa	5280
tatatgaagg aatataagat aaaggatttt tctaccttca gcaaaaacat acccactaat	5340
tagtaaaattt aataggcaaa aaaaagttgc atgctttat actgtaatga ttatcattt	5400
aaaacttagct ttttgccttc gagctatcg ggtaaagacc tacagggaaa ctactgtcga	5460
aatcctcgag gggagaagg gggaccctgg tgtttcacaa gcaatccaga ggtacgctac	5520
gaagtctgtt acattcctca gtgttcagaa gttgaatgca tgacactgaa tggggagagt	5580
tatcgaggc tcatacgatca tacagaatca ggcaagattt gtcagcgctg ggatcatcag	5640

US RE48,404 E

17

18

- continued

acaccacacc ggcacaaaatt cttgcctgaa agatatcccg acaaggcgtt tgatgataat	5700
tattggcgca atcccgatgg ccagccgagg ccatgggtgt atactcttga ccctcacacc	5760
cgctggagt actgtgcaat taaaacatgc gctgacaata ctatgaatga cactgtatgtt	5820
ccttggaaa caactgaatg catccaagggt caaggagaag gctacagggg cactgtcaat	5880
accatttgga atggaattcc atgtcagcgt tggatttc agtacctca cgagcatgac	5940
atgactcctg aaaatttcaa gtgcaaggac ctacgagaaa attactgccc aaatccagat	6000
gggtctgaat caccctggtg ttttaccact gatccaaaca tccgagttgg ctactgctcc	6060
caaattccaa actgtgatat gtcacatgga caagattttt atcgtggaa tggaaaaat	6120
tatatggca acttatccca aacaagatct ggactaacat gttcaatgtg ggacaagaac	6180
atggaagact tacatcgta tatttctgg gaaccagatg caagtaagct gaatgagaat	6240
tactgccgaa atccagatga tgatgctcat ggaccctggt gctacacggg aaatccactc	6300
attccttggg attattgccc tatttcttgt tgtgaagggtt ataccacacc tacaatagtc	6360
aatttagacc atcccgtaat atcttgtcc aaaacgaaac aattgcgagt tgtaaatggg	6420
attccaacac gaacaaacat aggatggatg gttagttga gatacagaaa taaacatatc	6480
tgcggaggat cattgataaa ggagagttgg gttcttactg cacgacagtg tttcccttct	6540
cgagacttga aagattatga agctggctt ggaattcatg atgtccacgg aagaggagat	6600
gagaaatgca aacaggttct caatgttcc cagctggat atggccctga aggatcagat	6660
ctggtttaa tgaagcttgc cagccctgct gtcctggatg attttgttag tacgattgt	6720
ttacctaatt atggatgcac aattcctgaa aagaccagtt gcagtgtta tggctgggc	6780
tacactggat tgatcaacta tgatggccta ttacgagttgg cacatctcta tataatggga	6840
aatgagaaat gcagccagca tcatcgaggg aaggtgactc tgaatgagtc tgaaatatgt	6900
gctggggctg aaaagattgg atcaggacca tgtgaggggg attatgggtt cccacttgg	6960
tgtgagcaac ataaaatgag aatggttttt ggtgtcattt ttcctggcg tggatgtgcc	7020
attccaaatc gtcctggat ttttgtccga gtagcatatt atgcaaaatg gatacacaaa	7080
attatTTAA catataaggt accacagtca tag	7113

<210> SEQ ID NO 3

<211> LENGTH: 34

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: gHGF3 primer

<400> SEQUENCE: 3

gtaaaggacg cgtctacaag ggaacagtat ctat

34

<210> SEQ ID NO 4

<211> LENGTH: 27

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: gHGF4 primer

<400> SEQUENCE: 4

actggatcct ctcggccata aacatct

27

<210> SEQ ID NO 5

<211> LENGTH: 34

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

- continued

<220> FEATURE:
 <223> OTHER INFORMATION: gHGF10 primer

<400> SEQUENCE: 5

gaagcttagc accatgtggg tgaccaaact cctg

34

<210> SEQ ID NO 6
 <211> LENGTH: 27
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: gHGF5 primer

<400> SEQUENCE: 6

tggccgagag gatccagat attaata

27

<210> SEQ ID NO 7
 <211> LENGTH: 27
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: gHGF7 primer

<400> SEQUENCE: 7

ccccctcgagg atttcgacag tagttt

27

<210> SEQ ID NO 8
 <211> LENGTH: 28
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: gHGF12 primer

<400> SEQUENCE: 8

gggatccctt cctttctacc tgtatttg

28

<210> SEQ ID NO 9
 <211> LENGTH: 25
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: gHGF13 primer

<400> SEQUENCE: 9

gggatcctgg gtaaacacat ttgaa

25

<210> SEQ ID NO 10
 <211> LENGTH: 28
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: gHGF6 primer

<400> SEQUENCE: 10

gggatccta tggtcagac aacttcga

28

<210> SEQ ID NO 11
 <211> LENGTH: 34
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: gHGF1 primer

<400> SEQUENCE: 11

gaagctgcc accatgtggg tgaccaaact cctg

34

- continued

<210> SEQ ID NO 12
<211> LENGTH: 34
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF2 primer

<400> SEQUENCE: 12

gggatccaga acgcgtcctt taccgatgtat gcag

34

<210> SEQ ID NO 13
<211> LENGTH: 35
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF8 primer

<400> SEQUENCE: 13

gggatccctt ctcgagactt gaaaagattat gaagc

35

<210> SEQ ID NO 14
<211> LENGTH: 32
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: gHGF9 primer

<400> SEQUENCE: 14

gtcttagagcg gccgctatga ctgtggtaacc tt

32

<210> SEQ ID NO 15
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: cHGF5 primer

<400> SEQUENCE: 15

ggatccacgc gtagcagcac catgtgggtg accaaa

36

<210> SEQ ID NO 16
<211> LENGTH: 36
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: cHGF3 primer

<400> SEQUENCE: 16

ggatcctcta gattacttca gctatgactg tggtac

36

<210> SEQ ID NO 17
<211> LENGTH: 26
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: GHGF5' primer

<400> SEQUENCE: 17

caaatgtcag ccctggagtt ccatga

26

<210> SEQ ID NO 18
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: GHGF3' primer

- continued

<400> SEQUENCE: 18

ctggattgct tggaaacag ggt 23

<210> SEQ ID NO 19

<211> LENGTH: 4679

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: HGF-X6 gene

<400> SEQUENCE: 19

atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcctc 60

ctgctccccca tcgccatccc ctatgcagag ggacaaagga aaagaagaaa tacaattcat 120

gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcact gaagataaaa 180

accaaaaaag tgaatactgc agaccaatgt gctaatacgat gtactaggaa taaaggactt 240

ccattcactt gcaaggcttt tggtttgtat aaagcaagaa aacaatgcct ctgggtcccc 300

ttcaatagca tgtcaagtgg agtgaaaaaaa gaatttggcc atgaatttga cctctatgaa 360

aacaaagact acattagaaa ctgcacatcatc ggtaaaggac gcagctacaa gggAACAGTA 420

tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgatacc acacgaacac 480

aggtaagaac agtatgaaga aaagagatga agcctctgtc tttttacat gttAACAGTC 540

tcataattgt ctttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat 600

tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata 660

tgttaataaa atgtagccaa aacaatatct taccttaatg cctcaatttg tagatctcg 720

tatttggta tcccttcctt tctacctgta tttgtcctaa taaattgttg acttattaat 780

tcactacttc ctcacagctt tttttggct ttacaaatcc actggaaagg tatatgggtg 840

tatcactttg tgtatttcgg tgtgcattgtg tagaggggac aaaaatcctc tctcaaacta 900

taaatattga gtatttgggt attgaacatt tgctataact actaggttcc ttaataatc 960

ttaatatata aaatgatata gaaaaaggaa aattatagtt cgtattttc atctaagtga 1020

agagattaaa acccaggggag taaataaatt gtctaaggac taaggttgc tactatttg 1080

gtgatagata tggggcaacc gtatgggtt tatgattaac aaataaactt ctcaccactc 1140

taccatatac acttttccat aaaagagagc tatagtattc tttgtctaaa taaattgtat 1200

tagtgcattga cttcttggaaa acatataaag caaaagtccac atttgattct atcagaaaa 1260

tgagtaagcc atggcccaaa caaaagatgc attaaaatat tctgaaatga tggagctaaa 1320

agtaagaaaa atgacttttt aaaaagttt actgttagga attgtgaaat tatgctgaat 1380

tttagttgca ttataatttt tgtcaagtcat acggctgtac aacctgtctt atttctattt 1440

ccccatatac ggaatgcttag ttaagtatgg atattaacta ttactactta gatgcattga 1500

agttgcataa tatggataat acttcactgg ttccctgaaa atgttttagtt agtaataagt 1560

ctcttacact atttgggggg tccaataatt tatattttctt gaagacttaa ctctagaata 1620

cactcatgtc aaaatgaaag aatttcattt caaaatattt cttgtacat gacgcataacc 1680

tgtattttgtt ttgtgtcaca acatgaaaaa tgatggttt ttagaagttt cattgggttag 1740

gaaacacatt tgaatggat ttaactaagat actaaaatcc ttggacttca ctctaaattt 1800

agtgcattt agaactcaag gtctcagtaa aagtagaaat aaagcctgtt aacaaaacac 1860

aagctgaata taaaaatgt aactggattt tcaaagaaat gtttactggc attacctgta 1920

- continued

gatgtatatt ctttattatg atctttgtg taaagtctgg cagacaaatg caatatctaa	1980
ttgttgagtc caatatcaca agcagtacaa aagtataaaa aagacttggc ctttctaatt	2040
gtgttaaat actttatgct ggtaataaca ctaagagtag ggcactagaa atttaagtg	2100
aagataatgt gttgcagtt ctgactcaa tggcttacta ttataaacca aaactggat	2160
cactaagctc cagtcagtc aaatgatcaa aattattgaa gagaataagc aattctgttc	2220
tttatttagga cacagtagat acagactaca aagtggagtg tgcttaataa gagtagcat	2280
ttgttaagtg tcaattactc tattatccct tggagcttct caaaataacc atataaggta	2340
taagatgtta aaggttatgg ttacactcg tgcacaggtt agctaataagg ctgagagaag	2400
ctaaattact tactgggtc tcacagtaag aaagttagt gaagtttcag cccagattt	2460
actggattct gggctttta ttcatgttac ttcatgaatc tgttctcaa ttgtgcagaa	2520
aaaagggggc tatttataag aaaagcaata aacaaacaag taatgatctc aaataagtaa	2580
tgcaagaaat agtgagattt caaaatcagt ggcagcgtt tctcagttct gtcctaagt	2640
gccttgctca atcacctgct atcttttagt ggagcttga aattatgttt cagacaactt	2700
cgattcagtt cttagatgtt tgactcagca aattcacagg ctcatcttc taacttgatg	2760
gtgaatatgg aaattcagct aaatggatgt taataaaatt caaacgtttt aaggacagat	2820
gaaaatgaca gaattttaag gtaaaatata tgaaggaata taagataaag gattttcta	2880
ccttcagcaa aaacataccc actaattagt aaaattaata ggcaaaaaaa agttgcattc	2940
tcttatactg taatgattat cattttaaa ctagtttt gcctcgagc tatcggttta	3000
aagacctaca ggaaaactac tgtcgaaatc ctcgagggga agaagggggc ccctgggtt	3060
tcacaagcaa tccagaggtt cgctacgaag tctgtgacat tcctcagttt tcagaagtt	3120
aatgcatttgc ctgcaatggg gagagtttgc gaggtctcat ggatcataca gaatcaggca	3180
agatttgtca gcgctggat catcagacac cacaccggca caaattcttgc cctgaaagat	3240
atcccgacaa gggctttgtt gataattatt gccgcaatcc cgatggccag ccgaggccat	3300
gggtctatac tcttgaccct cacacccgtt gggagttactg tgcaattttt acatgcgtt	3360
acaataactat gaatgacact gatgttcattt tggaaacaac tgaatgcattc caaggtaag	3420
gagaaggcta caggggact gtcaatacca tttggatgg aattttttttt cagcgttggg	3480
attctcagta tcctcacgag catgacatga ctccatggaa tttcaagtgc aaggacctac	3540
gagaaaaattt ctgccaaat ccagatgggt ctgaatcacc ctgggtttt accactgatc	3600
caaacatccg agttggctac tgctccaaa ttccaaactg tgatatgtca catggacaag	3660
attgttatcg tggaaatggc aaaaattata tggcaactt atccaaaca agatctggac	3720
taacatgttc aatgtggac aagaacatgg aagacttaca tcgtcatatc ttctggaaac	3780
cagatgcaag taagctgaat gagaattact gccgaaatcc agatgtgtt gctcatggac	3840
cctggtgcta cacggaaat ccactcattt cttggattt ttgcctatt tctcggttgc	3900
aaggtgatac cacacccata atagtcaatt tagaccatcc cgtaatattt tggccaaaa	3960
cggaaacatt gcgagttgtt aatgggatttcc caacacgaaac aaacatagga tggatggta	4020
gtttgagata cagaaataaa catatctgcg gaggatcatt gataaaggag agttgggtt	4080
ttactgcacg acagtgtttc ctttcgttgcg acttgaaaga ttatgttgc tggcttggaa	4140
ttcatgtatgtt ccacggaaaga ggagatgaga aatgcaaaaca gggttcaat gtttcccagc	4200
tggatatgg ccctgaagga tcagatctgg tttaatgaa gcttgccagg cctgctgtcc	4260
tggatgattt tgtagtacg attgatttac ctaattatgg atgcacaatt cctgaaaaga	4320

- continued

ccagttgcag tggatgttgc tggggctaca ctggattgtat caactatgtat ggcctattac	4380
gagtgccaca tctctatata atggaaatg agaaatgcag ccagcatcat cgaggaaagg	4440
tgactctgaa tgagtctgaa atatgtgctg gggctgaaaa gattggatca ggaccatgtg	4500
agggggatta tggtggccca cttgtttgtg agcaacataa aatgagaatg gttcttggtg	4560
tcattgttcc tggtcgtgga tgtgccattc caaatcgatcc tggtatcccc gtccgagtag	4620
catattatgc aaaatggata cacaaaatta tttaacata taaggtacca cagtcata	4679

<210> SEQ ID NO 20

<211> LENGTH: 3679

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: HGF-X7 gene

<400> SEQUENCE: 20

atgtgggtga ccaaactcct gccagccctg ctgctgcagc atgtcctcct gcatctcc	60
ctgctccca tcgcccattcc ctagcagag ggacaaagga aaagaagaaa tacaattcat	120
gaattcaaaa aatcagcaaa gactacccta atcaaaatag atccagcaact gaagataaaa	180
accaaaaaag tgaataactgc agaccaatgt gctaataatgt gtactaggaa taaaggactt	240
ccattcactt gcaaggctt tgttttgtat aaagcaagaa aacaatgcct ctggttcccc	300
ttcaatagca tgtcaagtgg agtgaaaaaaa gaatttggcc atgaatttga cctctatgaa	360
aacaaagact acattagaaa ctgcattcatc ggtaaaggac gcagctacaa gggAACAGTA	420
tctatcacta agagtggcat caaatgtcag ccctggagtt ccatgataacc acacgaacac	480
aggttaagaac agtatgaaga aaagagatga agcctctgtc ttttttacat gttaacagt	540
tcatattatgt ctttcagaat aattctacaa tcctaaaata acttagccaa cttgctgaat	600
tgtattacgg caaggtttat atgaattcat gactgatatt tagcaaatga ttaattaata	660
tgttaataaa atgttagccaa aacaatatct taccttaatg cctcaatttg tagatctcg	720
tatttgttga tccctgggttag gaaacacatt tgaatggat ttactaagat actaaaatcc	780
ttggacttca ctctaaatttt agtgcattt agaactcaag gtctcagttaa aagtagaaat	840
aaagcctgtt aacaaaacac aagctgaata taaaaatgt aactggattt tcaaagaaat	900
gtttactggc attacctgtt gatgtatatt ctttattatgt atctttgtg taaagtctgg	960
cagacaaatg caatatctaa ttgttgagtc caatatcaca agcagtcacaa aagtataaaa	1020
aagacttggc ctttctaat gtgttaaaaat actttatgtt ggtataaca ctaagagtag	1080
ggcactagaa attttaagtg aagataatgt gttgcagttt ctgcactcaa tggcttacta	1140
ttataaacca aaactggat cactaagctc cagtcagtc aaatgatcaa aattattgaa	1200
gagaataagc aattctgttc tttatttagga cacagtagat acagactaca aagtggagtg	1260
tgcttaataaa gaggttagcat ttgttaagtg tcaattactc tattatccct tggagcttct	1320
caaaataacc atataaggtg taagatgtt aaggttatgg ttacactcag tgcacaggtt	1380
agctaataagg ctgagagaag ctaaattact tactgggttc tcacagtaag aaagttagt	1440
gaagtttcag cccagatttta actggattct gggctttta ttcatgttac ttcatgaatc	1500
tgtttctcaa ttgtgcagaa aaaagggggc tatttataag aaaagcaata aacaaacaag	1560
taatgatctc aaataaagtaa tgcaagaaat agttagattt caaaatcagt ggcagcgatt	1620
tctcagttct gtccttaagtg gccttgctca atcacctgtt atcttttagt ggagcttga	1680

- continued

aattatgttt cagacaacctt cgattcagtt ctagaatgtt tgactcagca aattcacagg	1740
ctcatcttc taacttgatg gtgaatatgg aaattcagct aaatggatgt taataaaattt	1800
caaacgtttt aaggacagat gaaaatgaca gaatttaag gtaaaatata tgaaggaata	1860
taagataaaag gatTTTCTA CCTTCAGCAA AAACATACCC ACTAATTAGT AAAATTAATA	1920
ggcaaaaaaa agttgcattgc tcttatactg taatgattat cattttaaa ctagtttt	1980
gccttcgagc tatcgggta aagacctaca ggaaaactac tgtcgaaatc ctcgagggta	2040
agaaggggaa ccctgggtt tcacaagcaa tccagaggta cgctacgaag tctgtgacat	2100
tcctcagtgt tcagaagttt aatgcattgc ctgcaatggg gagagttatc gaggtctcat	2160
ggatcataca gaatcaggca agatttgcata ggcgtggat catcagacac cacaccggca	2220
caaattcttgcctgaaagat atcccgacaa gggctttgtt gataattattt gcccgaatcc	2280
cgtggccag ccgaggccat ggtgtatac tcttgaccct cacacccgct gggagtactg	2340
tgcaattaaa acatgcgttgc acaatactat gaatgacact gatgttcctt tggaaacaac	2400
tgaatgcattc caaggtcaag gagaaggcta caggggact gtcaatacca tttggaatgg	2460
aattccatgt cagcgttggg atttcagta tcctcacgag catgacatga ctccgtttttt	2520
tttcaagtgc aaggacctac gaaaaatttta ctggcgaaat ccagatgggt ctgaatcacc	2580
ctgggtttt accactgatc caaacatccg agttggctac tgctccaaa ttccaaactg	2640
tgtatgtca catggacaag attgttatcg tggaaatggc aaaaattata tggcaactt	2700
atcccaaaca agatctggac taacatgttc aatgtggac aagaacatgg aagacttaca	2760
tcgtcatatc ttctggAAC cagatgcaag taagctgaat gagaattact gccgaaatcc	2820
agatgtatgt gctcatggac cctggtgcta cacggaaat ccactcattt cttggattttt	2880
ttggccctatt ttcgttgtt aaggtgatac cacacctaca atagtcatt tagaccatcc	2940
cgtaatatct tggccaaaaa cgaaacaatt gcggatgtt aatgggattt caacacgaac	3000
aaacatagga tggatggta gtttgagata cagaaataaa catactgcg gaggatcatt	3060
gataaaggag agttgggttc ttactgcacg acagtgttc ctttcgttgc acttggaaaga	3120
ttatgaagct tggcttgaa ttcatgtatgtt ccacggaaaga ggagatgaga aatgcaaaaca	3180
ggttctcaat gtttccaggc tggatatgg ccctgaagga tcagatctgg tttaatgaa	3240
gtttgccagg cctgctgtcc tggatgattt tgtagtacg attgatttac ctaattatgg	3300
atgcacaatt cctgaaaaga ccagttgcag tgtttatggc tggggctaca ctggatttgc	3360
caactatgtt ggcctattttt ggtggcaca tctctatata atggaaatg agaaatgcag	3420
ccagcatcat cgagggaaagg tgactctgaa tgagtctgaa atatgtctg gggctgaaaa	3480
gattggatca ggaccatgtt agggggatta tggtggccca cttgtttgtt agcaacataa	3540
aatgagaatg gttcttggtt tcattgttcc tggtcgttggaa tggccattt caaatcgcc	3600
tggatTTTTT gtccgagtag catattatgc aaaatggata cacaaaattt ttttaacata	3660
taaggtacca cagtcatacg	3679

<210> SEQ_ID NO 21
 <211> LENGTH: 2729
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: HGF-X8 gene

<400> SEQUENCE: 21

atgtgggtga ccaaactcctt ggcagccctt ctgctgcacg atgttccttgc ctttccttc 60

- continued

ctgctcccc	tcggccatccc	ctatgcagag	ggacaaagga	aaagaagaaa	tacaattcat	120
gaattcaaaa	aatcagcaaa	gactacccta	atcaaatacg	atccaggact	gaagataaaa	180
accaaaaaaag	tgaataactgc	agaccaatgt	gctaatacgat	gtactaggaa	taaaggactt	240
ccattcactt	gcaaggctt	tgttttgat	aaagcaagaa	aacaatgcct	ctggttcccc	300
ttcaatagca	tgtcaagtgg	agtgaaaaaa	gaatttggcc	atgaatttga	cctctatgaa	360
aacaaagact	acattagaaa	ctgcatcatc	ggtaaaggac	gcagctacaa	gggaacagta	420
tctatcacta	agagtggcat	caaatgtcag	ccctggagtt	ccatgatacc	acacgaacac	480
aggttaagaac	agtatgaaga	aaagagatga	agcctctgtc	ttttttacat	gttaacagtc	540
tcatattagt	ccttcagaat	aattctacaa	tcctaaaata	acttagccaa	cttgctgaat	600
tgtattacgg	caaggtttat	atgaattcat	gactgatatt	tagcaaatacg	ttaattaata	660
tgttaataaa	atgttagccaa	aacaatatct	taccttaatg	cctcaatttg	tagatctcg	720
tatttgtgga	tccttatgtt	tcagacaact	tcgattcagt	tctagaatgt	ttgactcagc	780
aaattcacag	gctcatctt	ctaacttgat	ggtgaatatg	gaaattcagc	taaatggatg	840
ttaataaaat	tcaaacgttt	taaggacaga	tgaaaatgac	agaattttaa	ggtaaaaat	900
atgaaggaat	ataagataaa	ggattttct	accttcagca	aaaacatacc	cactaattag	960
taaaaattaaat	aggcaaaaaaa	aagttgcatt	ctcttatact	gtaatgatta	tcattttaaa	1020
actagctttt	tgccttcgag	ctatcggtt	aaagacctac	aggaaaacta	ctgtcgaaat	1080
cctcgaggggg	aagaagggggg	accctgggt	ttcacaagca	atccagaggt	acgctacgaa	1140
gtctgtgaca	ttcctcagtg	ttcagaagtt	gaatgcatt	cctgcaatgg	ggagagttat	1200
cgaggtctca	tggatcatac	agaatcaggc	aagatttgc	agcgctggg	tcatcagaca	1260
ccacaccggc	acaaattctt	gcctgaaaga	tatccgaca	aggcatttga	tgataattat	1320
tgccgcaatc	ccgatggcca	gccgaggcca	tggtgctata	ctcttgaccc	tcacaccgc	1380
tgggagttact	gtgcaattaa	aacatgcgt	gacaatacta	tgaatgacac	tgatgttcct	1440
ttggaaacaa	ctgaatgcat	ccaaggtcaa	ggagaaggct	acaggggcac	tgtcaatacc	1500
atttggaaatg	gaattccatg	tcagcggtgg	gattctcagt	atcctcacga	gcatgacatg	1560
actcctgaaa	atttcaagtg	caaggaccta	cgagaaaatt	actgccaaa	tccagatggt	1620
ctgaatcacc	ctgggtttt	accactgatc	caaacatccg	agttggctac	tgctcccaa	1680
ttccaaactg	tgatatgtca	catggacaag	attgttatcg	tgggaatggc	aaaaattata	1740
tggcaacctt	atcccaaaca	agatctggac	taacatgttc	aatgtggac	aagaacatgg	1800
aagacttaca	tcgtcatatc	ttctggaaac	cagatgcaag	taagctgaat	gagaattact	1860
gccgaaatcc	agatgatgt	gctcatggac	cctggtgct	cacggaaat	ccactcatc	1920
cttgggatta	ttgcccattt	tctcggttg	aagggtatac	cacacctaca	atagtcaatt	1980
tagaccatcc	cgtaatatct	tgtgcaaaaa	cgaaacaatt	gcgagttgt	aatggattc	2040
caacacgaac	aaacatagga	tggatggta	gtttgagata	cagaaataaa	catactg	2100
gaggatcatt	gataaaggag	agttgggttc	ttactgcacg	acagtgttc	ccttctcgag	2160
acttgaaaga	ttatgaagct	tggcttgaa	ttcatgatgt	ccacgaaaga	ggagatgaga	2220
aatgcaaaca	ggttctcaat	gtttccagc	tggtatatgg	ccctgaagga	tcagatctgg	2280
tttaatgaa	gcttgccagg	cctgctgtcc	tggatgattt	tgttagtacg	attgattac	2340
ctaattatgg	atgcacaatt	cctgaaaaga	ccagttgcag	tgttatggc	tgggctaca	2400

- continued

ctggatttat caactatgtat ggccttattac gagtggcaca tctctatata atggaaatg	2460
agaaatgcag ccagcatcat cgagggagg tgactctgaa tgagtctgaa atatgtgtcg	2520
gggctgaaaa gattggatca ggaccatgtg agggggatta tggtgccca cttgttttg	2580
agcaacataa aatgagaatg gtttttgtg tcattgttcc tggcgtgga tgtgccatc	2640
caaatcgccc tggtattttt gtccgagtag catattatgc aaaatggata cacaaaattt	2700
tttaacata taaggtacca cagtcata	2729

What is claimed is:

1. A method for co-expressing two heterotypes of Hepatoctye Growth Factor (HGF) *in vivo in a mammalian subject with ischemic disease in order to treat the disease*, comprising:

transforming or transfecting [to] a DNA construct into a cell of a mammalian subject with ischemic disease by administering a DNA construct to the subject, the DNA construct comprising:

- (a) a promoter,
- (b) a first cDNA which has the same sequence as exons 1-4 of the human HGF gene wherein said exons 1-4 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said first cDNA,
- (c) a polynucleotide that has the same sequence as intron 4 of the HGF gene or a functional fragment thereof, and
- (d) a second cDNA which has the same sequence as exons 5-18 of the human HGF gene wherein said exons 5-18 are arranged in sequential order without an intron therebetween, or degenerates thereof which do not alter the amino acid sequence encoded by said second cDNA;

wherein (c) is located between (b) and (d); and the HGF construct simultaneously encodes two heterotypes of human HGF, and

whereby two heterotypes of human HGF are co-expressed within the mammalian subject, thereby treating the ischemic disease.

2. The method of claim 1, wherein said intron has the same sequence as a fragment of intron 4 of the HGF gene.

3. The method of claim 2, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 19.

4. The method of claim 3, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 19.

5. The method of claim 4, wherein the construct comprises the sequence of SEQ ID NO: 19.

6. The method of claim 2, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 20.

15 7. The method of claim 6, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 20.

8. The method of claim 7, wherein the construct comprises the sequence of SEQ ID NO: 20.

9. The method of claim 2, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 21.

10. The method of claim 9, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 21.

11. The method of claim 10, wherein the construct comprises the sequence of SEQ ID NO: 21.

12. The method of claim 1, wherein the one intron has the same sequence as the full intron 4 of the HGF gene.

13. The method of claim 1, wherein the construct comprises a nucleotide sequence not less than 90% identical to SEQ ID NO: 2.

14. The method of claim 13, wherein the construct comprises a nucleotide sequence not less than 95% identical to SEQ ID NO: 2.

15. The method of claim 14, wherein the construct comprises the sequence of SEQ ID NO: 2.

16. The method of claim 1, wherein the construct further comprises a terminator sequence, a self-replication sequence, or a secretory signal.

17. The method of claim 1, wherein the expression efficiency of the construct is higher than the expression efficiency of HGF cDNA or deleted variant HGF (dHGF) cDNA.

18. The method of claim 1, wherein the expression level of the construct is about 20- to 100-fold higher than the expression level of the HGF cDNA or dHGF cDNA.

[19. The method of claim 1, wherein the cell is a mammalian cell, a bacterial cell or a yeast cell.]

[20. The method of claim 19, wherein the cell is a mammalian cell.]

[21. The method of claim 20, wherein the transformation of said mammalian cell is *in vivo*.]

* * * * *